{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Vilsboll T"],"funding":["Novo Nordisk A/S"],"pagination":["3165-3175"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12046478"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(6)"],"pubmed_abstract":["<h4>Aims</h4>To assess the treatment effects of once-weekly insulin icodec (icodec) versus once-daily basal insulin comparators in individuals with type 2 diabetes (T2D) according to baseline glucagon-like peptide-1 receptor agonist (GLP-1RA) and sodium-glucose co-transporter-2 inhibitor (SGLT2i) use.<h4>Materials and methods</h4>This post hoc analysis of the randomized ONWARDS 1-5 trials of individuals with T2D assessed treatment outcomes by trial according to baseline GLP-1RA and/or SGLT2i use.<h4>Results</h4>At screening, 21.3% (801/3765) and 36.9% (1388/3765) of participants in ONWARDS 1-5 were treated with a GLP-1RA or an SGLT2i, respectively. Baseline characteristics were broadly similar across treatment arms irrespective of GLP-1RA/SGLT2i use; GLP-1RA users had numerically higher bo"],"journal":["Diabetes, obesity & metabolism"],"pubmed_title":["Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in type 2 diabetes according to baseline glucagon-like peptide-1 receptor agonist and sodium-glucose co-transporter-2 inhibitor use: A post hoc analysis of ONWARDS 1-5."],"pmcid":["PMC12046478"],"funding_grant_id":["N/A"],"pubmed_authors":["Fu A","Kellerer M","Vilsboll T","Sogaard SB","Goldenberg R","Kumar B"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in type 2 diabetes according to baseline glucagon-like peptide-1 receptor agonist and sodium-glucose co-transporter-2 inhibitor use: A post hoc analysis of ONWARDS 1-5.","description":"<h4>Aims</h4>To assess the treatment effects of once-weekly insulin icodec (icodec) versus once-daily basal insulin comparators in individuals with type 2 diabetes (T2D) according to baseline glucagon-like peptide-1 receptor agonist (GLP-1RA) and sodium-glucose co-transporter-2 inhibitor (SGLT2i) use.<h4>Materials and methods</h4>This post hoc analysis of the randomized ONWARDS 1-5 trials of individuals with T2D assessed treatment outcomes by trial according to baseline GLP-1RA and/or SGLT2i use.<h4>Results</h4>At screening, 21.3% (801/3765) and 36.9% (1388/3765) of participants in ONWARDS 1-5 were treated with a GLP-1RA or an SGLT2i, respectively. Baseline characteristics were broadly similar across treatment arms irrespective of GLP-1RA/SGLT2i use; GLP-1RA users had numerically higher bo","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jun","modification":"2026-06-01T06:18:14.323Z","creation":"2025-07-06T03:06:01.637Z"},"accession":"S-EPMC12046478","cross_references":{"pubmed":["40098267"],"doi":["10.1111/dom.16328"]}}